Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 4/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.31 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.31 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.31 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | PRKX | P51817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22895152 | 0.89 | CXCR2 (0.39) | CXCR2PLK1CHEK1DAPK3ROCK2 | |
| SCHEMBL25955183 | 0.84 | HDAC1 (0.38) | — | |
| SCHEMBL25477849 | 0.80 | CXCR2 (0.33) | CXCR2PLK1 | |
| SCHEMBL409685 | 0.80 | — | — | |
| SCHEMBL19956914 | 0.75 | HDAC1 (0.33) | — | |
| SCHEMBL26546660 | 0.73 | HTT (0.35) | CXCR2PLK1CHEK1DAPK3ROCK2 | |
| SCHEMBL17899042 | 0.73 | PLK1 (0.37) | CXCR2PLK1CHEK1DAPK3ROCK2 | |
| SCHEMBL10209850 | 0.72 | GAA (0.41) | CXCR2GAAHSD17B10KDM4ECYP1A2 | |
| SCHEMBL19956902 | 0.69 | KDM4E (0.38) | GAAKDM4ECYP1A2CYP2D6 | |
| SCHEMBL17532555 | 0.69 | POLB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240024489-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | INSTITUT PASTEUR (FR) | 2024-01-25 | — | — | US | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230242474-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | GUANGZHOU RIBOBIO CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242474-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | GUANGZHOU RIBOBIO CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023118195-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms for Cure GmbH (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023078271-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海旭成医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
| WO-2017046535-A1 | MULTI-FUNCTIONALIZED POLYSACCHARIDE COMPOUNDS AND USE THEREOF FOR TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR | NANOMEDSYN (FR) | 2017-03-23 | — | — | WO | disclosed |
| EP-2305697-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305698-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ABL1, LCK, ERBB2 | CXCR2 1145/4885PLK1 131/4885CHEK1 393/4885 |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | ABL1, LCK, ERBB2 | CXCR2 1145/4885PLK1 131/4885CHEK1 393/4885 |
| US-20240024489-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | SI, DAD1, FUT5 | CXCR2 2720/4885PLK1 1139/4885CHEK1 4558/4885 |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | CXCR2 969/4885PLK1 1419/4885CHEK1 3061/4885 |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | CFTR, TSLP, MTREX | CXCR2 498/4885PLK1 1356/4885CHEK1 3981/4885 |
| US-20230242474-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | NPC1L1, NPC1, SGMS1 | CXCR2 995/4885PLK1 1410/4885CHEK1 4759/4885 |
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | CXCR2 3450/4885PLK1 737/4885CHEK1 3525/4885 |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, ABHD16A | CXCR2 1803/4885PLK1 1743/4885CHEK1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.